In addition to its discovery-stage FMRP program, Opna’s lead clinical compound, OPN-2853, a bromo and extra terminal (BET) domain inhibitor, is currently in a Phase 1/2 trial with ruxolitinib (Jakafi®) in myelofibrosis, a chronic bone marrow disorder. The company also expects to initiate a Phase 2 study with OPN-7486, a colony stimulating factor 1 (CSF1) receptor inhibitor, in patients with histiocytosis, a white blood cell disorder, in the first half of 2023.
EXPLORE
Hanahan et al, November 2022
Upregulation of the neuronal fragile X mental retardation protein in cancer cells suppresses proinflammatory signals to circumvent tumor immunity
Read MoreGideon Bollag, PhD, Named CEO and Board Director.
